Semaglutide
Abdominal Obesity-Metabolic Syndrome
Explore 42 assets in Abdominal Obesity-Metabolic Syndrome →Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Hallym University
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07589322CT.gov Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | — | Recruiting | — | — | — |
NCT07513168CT.gov Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani Adults | — | Recruiting | — | — | — |
NCT06410352CT.gov Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome | — | Recruiting | — | — | — |
NCT06072963CT.gov COMMETS- Combination MCI Metabolic Syndrome | — | Recruiting | — | — | — |
NCT06354101CT.gov The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study. | — | Withdrawn | — | — | — |
NCT03292315CT.gov Once Weekly GLP-1 in Persons With Spinal Cord Injury | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Abdominal Obesity-Metabolic Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Semaglutide (this asset) | Hallym University | Approved | BB · 68 |
| Topiramate | All India Institute of Medical Sciences, Bhubaneswar | P4 | BBB |
| Atorvastatin | Seoul National University Hospital | P4 | BBB |
| Pioglitazone | Philip Kern | P4 | BBB |
| Simvastatin | Jaime Daniel Mondragon | P4 | BBB |
| Olmesartan Medoxomil | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | P4 | BBB |
| Rosuvastatin | Hamdard University | P4 | BBB |
| Amlodipine | Italo Biaggioni | P4 | BB |
| Ezetimibe | Samsung Medical Center | P4 | BB |
+42 more in the Abdominal Obesity-Metabolic Syndrome cohort
Other indications for Semaglutide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Disease | — | P4 | A · 81 |
| Polycystic Ovary Syndrome | — | P4 | BBB · 79 |
| Type 2 Diabetes Mellitus | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Semaglutide in Abdominal Obesity-Metabolic Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/semaglutide-abdominal-obesity-metabolic-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →